Table 3 Comparative costs (US$) for first-line treatment of MCRC with XELOX and FOLFOX4 from a healthcare payer perspective
| Â | Â | XELOX (n = 30) Mean (SD) | FOLFOX4 (n = 30) Mean (SD) |
|---|---|---|---|
Scheduled costs per cycle | |||
Chemotherapy cost | 1,184 (152) | 724 (84) | |
Hospital days for chemotherapy delivery | 180 (-)* | 848 (-)* | |
Hospital tests | 55 (106) | 76 (163) | |
Outpatient visits | 155 (52) | 135 (46) | |
Outpatient tests at scheduled visits | 472 (291) | 368 (191) | |
Total scheduled cost per cycle | 2,046 (325) | 2,152 (307) | |
Total scheduled cost per patient | 14,866 (3,823) | 19,801 (5,405) | |
Other unscheduled costs | |||
Drug costs | 4 (7) | 44 (191) | |
Hospital days | 201 (355) | 355 (670) | |
Outpatient visits | 15 (21) | 13 (39) | |
Outpatient tests at unscheduled visits | 20 (53) | 9 (28) | |
Total unscheduled cost per cycle | 240 (364) | 421 (890) | |
Total unscheduled cost per patient | 1,743 (2,197) | 3,871 (3,870) | |
Total cost per patient | 16,609 (4,710) | 23,672 (5,904) | |